Articles

31. Systematic Strategy To Reduce The Cost Of Goods Sold 3/26/2026

    Learn key ways to cut biologics manufacturing costs through smarter process design, material choices, and supply resilience — driving more efficient, reliable, and commercially sustainable production.

32. Overcoming API Constraints And Tight Timelines With On-Demand Manufacturing 3/20/2026

    Use innovative lipid-based formulations and on-demand manufacturing to accelerate Phase 1 trials, enable flexible dose escalation, and maximize limited API for poorly soluble compounds.

33. Small Molecule API Production: Unveiling The Impact Of Fermentation 3/17/2026

    Technological developments have led to growth in the suitability of fermentation for a myriad of applications. Explore the impact of the evolution of synthetic biology and supporting technologies on modern fermentation practice.

34. Accelerated API Manufacturing: Combining All Process Development Stages 3/17/2026

    During early-stage development, utilize the key considerations outlined in this paper to avoid common pitfalls and expedite the transition from molecule to market.

35. Improvements In ADC Efficacy And Stability 3/17/2026

    Antibody–drug conjugates link antibodies to potent toxins, but increased hydrophobicity impairs stability, manufacturing, and PK, spurring interest in hydrophilic linker strategies.

36. Spotlight On Fremont: Biologics, Tailored By Mammalian Cell Culture Experts 3/17/2026

    Lilith Baczynski highlights how the Fremont site’s scale, flexibility, and expert teams support global mammalian biologics manufacturing.

37. Steroids: Development And Manufacturing 3/17/2026

    As a dedicated center of excellence in this product family, we offer a high degree of versatility and tailored solutions to meet the specific needs of each client.

38. Don't Let Formulation Failures Derail Drug Development 3/13/2026

    In the face of increasing molecular complexity, early developability assessment with a skilled CDMO can reduce pharmaceutical development costs, prevent clinical delays, and improve commercial success.

39. API Sterilization 3/13/2026

    Leverage advanced aseptic processing and Quality Risk Management–driven controls that help ensure sterile-grade APIs when terminal sterilization is not a viable option.

40. Patented Process For Intermediates Useful For Deucravacitinib 3/13/2026

    Discover how this patented synthetic approach to Deucravacitinib intermediates can improve yield, simplify purification, and support scalable, regulatory-aligned manufacturing.